Trial intelligence / Profile preview

Salvianolic acid injection for recovery-phase ischemic stroke

ChiCTR1900026178Phase 4Completed

Sponsor
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Start
Aug 2019
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of danshen polyphenolic acid in ischemic stroke, sponsored by Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoint: Modified Rankin Scale. Started Aug 2019; status: completed.

02

Drugs

danshen polyphenolic acid
03

Conditions

ischemic stroke

Beyond the preview

Go deeper on ChiCTR1900026178.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR1900026178.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call